07:00 , Jun 16, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

Hepatic disease INDICATION: Liver fibrosis Mouse studies suggest in vivo reprogramming of liver myofibroblasts into hepatocyte-like cells could help treat liver fibrosis. In a mouse model of the disease, in vivo transduction of myofibroblasts with...
07:00 , Mar 20, 2014 |  BC Innovations  |  Cover Story

A liver divided

Three separate teams have directly converted human fibroblasts to proliferative liver cells and thus eliminated a key drawback of using induced pluripotent stem cells to treat damaged livers-the inability of the resulting differentiated cells to...
08:00 , Jan 27, 2014 |  BioCentury  |  Emerging Company Profile

TCF: HIV against autoimmunity

TCF GmbH is developing a recombinant version of the HIV envelope protein that, when used on its own, can function as a therapeutic to reestablish immune tolerance in autoimmune diseases. Preclinical studies showed the therapeutic...
07:00 , Mar 14, 2013 |  BC Innovations  |  Targets & Mechanisms

Placing kinases in the WNT pathway

Despite the well-established role of WNT signaling in many cancers, the pathway has proven difficult to modulate therapeutically because it is largely composed of hard-to-target protein-protein interactions. Now, a Boston-based team and a group led...
08:00 , Feb 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Promoting telomerase

Two independent teams have identified activating mutations in the promoter of telomerase reverse transcriptase that occur in more than 70% of melanoma cases. 1,2 The findings highlight the still-untapped potential of analyzing noncoding regions of...
08:00 , Dec 15, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Hepatocyte nuclear factor 4a (HNF4A; TCF); microRNA-124 (miR-124) Mouse and patient sample studies suggest increasing signaling in the HNF4A-miR-124 pathway could help treat...
08:00 , Jan 6, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Patient-derived cell lines as an in vitro model for drug screening for genetically complex diseases Screening small molecules in patient-derived cell lines could help...
08:00 , Jan 6, 2011 |  BC Innovations  |  Tools & Techniques

Modeling genetic complexity in vitro

Harvard researchers believe they have developed a method for generating in vitro models of highly complex genetic diseases, which are difficult to model with standard genetic knockout techniques. 1 With proof of principle in a...
08:00 , Dec 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis Cadherin 1, type 1, E-cadherin (CDH1); cadherin 3, type 1, P-cadherin (CDH3); hepatocyte nuclear factor 4a (HNFA); laminin b1 (LAMB1) Genomewide association studies...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Hybrigenics, Kiadis Pharma deal

Kiadis acquired assets related to the Wnt signal transduction pathway from Hybrigenics for an undisclosed upfront payment. The assets include an undisclosed number of discovery-stage compounds that inhibit the interaction between beta-catenin and Tcf, plus...